Cite
MLA Citation
Thomas Powles et al.. “Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet oncology, vol. 23, no. 9, 2022, pp. 1133–1144. http://access.bl.uk/ark:/81055/vdc_100164415485.0x000023